Some Insurers Still Reluctant to Pay for New Biologic Drugs


Maui, Hawaii - Some insurers are reluctant to pay for the new biologic drugs for psoriasis, despite the approval of two of the drugs by the U.S. Food and Drug Administration, according to William Abramovits, M.D.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.